A Multicenter Phase II Study of Second‐Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First‐Line Sorafenib Monotherapy

LESSONS LEARNED: For patients with advanced hepatocellular carcinoma after failure of first‐line sorafenib monotherapy, second‐line axitinib provides modest efficacy with tolerable toxicity. The discrepant tumor responses and survival outcomes in trials using axitinib as salvage therapy highlight th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Lin, Zhong‐Zhe, Chen, Bang‐Bin, Hung, Yi‐Ping, Huang, Po‐Hsiang, Shen, Ying‐Chun, Shao, Yu‐Yun, Hsu, Chih‐Hung, Cheng, Ann‐Lii, Lee, Rheun‐Chuan, Chao, Yee, Hsu, Chiun
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485356/
https://ncbi.nlm.nih.gov/pubmed/32271494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0143
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados